Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [5] [6] [10] It appears to result in a small benefit in mental function and ability to function. [11] Use, however, has not been shown to change the progression of the disease. [12] Treatment should be stopped if no benefit ...
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...
Estimated prevalence rates of depression vary widely according to the population sampled and methodology used, although depressive symptoms, irrespective of classically defined DSM criteria for depression, are present in 35% of patients [13] There is an increased risk for any individual with depression to go on to develop Parkinson's disease at ...
The four cardinal motor symptoms of Parkinson's—bradykinesia (slowed movements), postural instability, rigidity, and tremor—are called parkinsonism. [9] [10] These four symptoms are not exclusive to Parkinson's and can occur in many other conditions, [11] [12] including HIV infection and recreational drug use.
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. ... More on drugs: Top aging expert says these 4 FDA-approved drugs hold promise for extending ...
Generally, drugs outlined within the ATC code N04 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Antiparkinsonian agents .
The available research seems to suggest that the concurrent prophylactic use of a neuroleptic and an antiparkinsonian drug is useless to avoid early extrapyramidal side-effects and may render the person more sensitive to tardive dyskinesia. Since 1973 the use of these drugs has been found to be associated with the development of tardive dyskinesia.
Acetylcholinesterase inhibitors are primarily used to treat symptoms of dementia, Alzheimer's disease, Parkinson's disease, and myasthenia gravis. [3] Butyrylcholinesterase inhibitors: Butyrylcholinesterease inhibitors prevent the degradation of butyrylcholine, which increases its concentration and duration of action in the neuromuscular junction.